Patents by Inventor Elena Tsifrina

Elena Tsifrina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Hyaluronan-Binding Proteins and Encoding Genes
    Publication number: 20070213255
    Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.
    Type: Application
    Filed: October 17, 2006
    Publication date: September 13, 2007
    Applicants: Human Genome Sciences, Inc., The American National Red Cross
    Inventors: Gregg Hastings, Gene Liau, Elena Tsifrina
  • Hyaluronan-binding proteins and encoding genes
    Patent number: 7153670
    Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: December 26, 2006
    Assignees: Human Genome Sciences, Inc., The American Red Cross
    Inventors: Gregg A. Hastings, Gene Liau, Elena Tsifrina
  • Novel hyaluronan-binding proteins and encoding genes
    Publication number: 20050239098
    Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.
    Type: Application
    Filed: October 8, 2004
    Publication date: October 27, 2005
    Applicants: Human Genome Sciences, Inc., The American Red Cross
    Inventors: Gregg Hastings, Gene Liau, Elena Tsifrina
  • Hyaluronan-binding proteins and encoding genes
    Patent number: 6872546
    Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: March 29, 2005
    Assignees: Human Genome Sciences, Inc., The American Red Cross
    Inventors: Gregg A. Hastings, Gene Liau, Elena Tsifrina